A

argenx

Develops antibody-based therapies for autoimmune diseases

Executive Director – CIDP Indication Lead - US HCP Marketing

Full-Time
No salary listed
Expert
Bachelor's, Master's, MBA, PharmD, PhD
Remote in USA
Remote
Growth & MarketingProduct Marketing

About the job

Requirements
  • Deep understanding of HCP marketing strategy, customer engagement, and commercial execution in specialty, rare disease, biologics, or similarly complex markets.
  • Strong knowledge of Neurology customer ecosystems, including neurologists, academic KOLs, referral networks, and other stakeholders influencing diagnosis, treatment decisions, and patient care.
  • Ability to develop integrated HCP engagement strategies across multiple brands, indications, customer segments, and lifecycle stages.
  • Strong strategic thinking and analytical problem-solving skills, including synthesizing customer insights, market dynamics, performance data, and cross-functional input into clear strategic direction.
  • Demonstrated ability to lead in a matrix environment, influence senior stakeholders, and align teams around shared priorities without relying solely on formal authority.
  • Experience shaping customer-centered HCP journeys, engagement plans, disease-state education, peer-to-peer strategies, congress strategies, and field enablement approaches.
  • Ability to translate complex clinical, product, access, and market information into clear messages and resources that support effective HCP engagement.
  • Strong understanding of personal and non-personal promotion, digital and omnichannel engagement, modular content, customer analytics, and agile marketing ways of working.
  • Experience partnering with Field, TLL, Medical, Market Access, Patient Experience, Digital, Insights, Legal, Regulatory, Compliance, and external agency partners.
  • Strong leadership presence, communication skills, and ability to coach, develop, and inspire teams in a fast-paced and evolving environment.
  • Ability to balance enterprise coordination with brand- and indication-specific accountability.
  • Flexibility to travel based on business needs.
  • A bachelor's degree is required.
  • Approximately 12–15+ years of relevant experience in biotech or pharmaceuticals, including significant HCP marketing, specialty marketing, launch planning, lifecycle management, or therapeutic area strategy experience.
  • Experience leading HCP commercial strategy and execution in rare disease, immunology, neurology, biologics, or other complex treatment markets.
  • Demonstrated experience building and executing integrated marketing strategies across multiple customer segments, channels, brands, indications, or lifecycle stages.
  • Experience with product launch and lifecycle management, preferably in rare disease, specialty biologics, or markets involving complex diagnosis and treatment pathways.
  • Strong understanding of HCP customer journeys, peer influence models, KOL engagement, field enablement, disease-state education, and omnichannel engagement.
  • Track record of leading cross-community teams in a matrix environment with stakeholders across Commercial, Field, Medical Affairs, Market Access, Patient Experience, Digital, Insights, Legal, Regulatory, and Compliance.
  • Experience managing budgets, strategic priorities, agency partners, and complex executional workstreams in a fast-paced commercial environment.
  • Demonstrated ability to develop talent, coach teams, and lead through organizational growth, ambiguity, and change.
Responsibilities
  • Lead HCP promotional strategy and execution to maximize growth for VYVGART Hytrulo in CIDP.
  • Monitor portfolio performance, market dynamics, customer feedback, and engagement data to identify opportunities to optimize CIDP strategy, priorities, and execution.
  • Collaborate with Global ICT and cross-functional partners to define the dual-asset strategy and co-positioning framework so the upcoming Empasiprubart launch in CIDP enhances franchise value.
  • Develop a franchise-level value narrative that differentiates the two CIDP brands while reinforcing their complementary strengths.
  • Lead HCP disease-awareness and unbranded education strategies to shape CIDP management and elevate unmet needs.
  • Ensure field teams have the messages, tools, training, and customer context needed to engage HCPs across customer segments effectively.
  • Co-create evidence-generation priorities with Medical and Development to support long-term differentiation.
  • Anticipate competitive shifts and adapt the ecosystem strategy accordingly.
  • Serve as a core strategic voice for the HCP customer within the CIDP Indication Strategy Team.
  • Provide clear direction, prioritization, and performance expectations for CIDP workstreams and cross-community initiatives.
  • Model an enterprise mindset, cross-functional influence, and disciplined prioritization.
  • Provide executive-ready strategic recommendations supported by analytics and scenario modeling.
  • Partner with the Customer Engagement & Experience Community Lead to ensure Neurology HCP engagement reflects enterprise experience standards, journey-design principles, voice of customer, and consistent engagement practices.
  • Lead, coach, and develop HCP Experience team members, including direct reports and matrixed contributors supporting HCP marketing, customer engagement, launch planning, lifecycle management, and field enablement.
  • Create development opportunities for team members and junior marketing talent supporting Neurology initiatives, including exposure to strategic planning, customer engagement, cross-community collaboration, and launch and lifecycle work.
  • Foster a culture of customer-centricity, accountability, co-creation, innovation, excellence, and humility.
  • Ensure the team operates with strong compliance, sound judgment, and a clear understanding of the regulatory environment for HCP marketing in complex biologics and rare disease markets.
Desired Qualifications
  • An advanced degree in a relevant field, such as an MBA, MPH, PharmD, PhD, or another advanced scientific or business degree.
  • Experience working in a rapidly scaling or evolving organization.

About the company

argenx develops and markets antibody-based therapies for severe autoimmune diseases. Its medicines work by modulating the immune system through engineered antibodies, notably efgartigimod (VYVGART for generalized myasthenia gravis and VYVGART Hytrulo for CIDP) that influence FcRn pathways. The company differentiates itself through antibody engineering capabilities and a co-creation model with academic and industry partners, plus a pipeline focused on FcRn-, complement-, and target-directed programs across autoimmune indications. Its goal is to provide effective antibody medicines that improve patient outcomes and expand global access through its development and commercial footprint.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Amsterdam, Netherlands

Founded

2008

Get referred to argenx

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • May 8, 2026 FDA approval opened VYVGART to all adult gMG serotypes.
  • August 17, 2026 ALKIVIA met primary endpoint in autoimmune myositis, adding a multibillion-dollar indication.
  • September 29, 2026 AANEM data extended VYVGART into ocular MG and longer-duration CIDP use.

What critics are saying

  • UCB's RYSTIGGO and J&J's nipocalimab attack the same FcRn market by 2027.
  • VYVGART concentration remains extreme; one franchise drove $2.8 billion first-half 2026 sales.
  • If ALKIVIA or upcoming myositis filings disappoint, argenx loses its next blockbuster expansion.

What makes argenx unique

  • VYVGART is first-and-only approved for all adult gMG serotypes after May 8, 2026.
  • argenx scaled $1.5 billion Q2 2026 product sales with 60% year-over-year growth.
  • August 27, 2026 Forte acquisition added FB102, broadening the immunology pipeline.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Business Insider
Oct 8th, 2026
Argenx Se (ARGX) receives a Buy from RBC Capital.

Argenx Se (ARGX) receives a Buy from RBC Capital. Oct. 8, 2026, 09:47 PM In a report released yesterday, Luca Issi from RBC Capital maintained a Buy rating on Argenx Se, with a price target of $1,100.00. According to TipRanks, Issi is an analyst with an average return of -5.6% and a 34.62% success rate. Issi covers the Healthcare sector, focusing on stocks such as Amgen, Arrowhead Pharmaceuticals, and Ionis Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Argenx Se with a $1,182.58 average price target. Based on Argenx Se's latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $2.82 billion and a net profit of $838.82 million. In comparison, last year the company earned a revenue of $947.96 million and had a net profit of $245.36 million Read More on ARGX:

Yahoo Finance
Oct 8th, 2026
Argenx shares drop 15% as Vyvgart fails Sjögren's trial despite celiac drug success

Argenx shares dropped 15% on Thursday after the Dutch biotech announced its blockbuster drug Vyvgart failed to help patients with Sjögren's disease. An independent monitoring board recommended ending the Phase 3 study "for futility" following an interim analysis. The timing surprised analysts, who weren't expecting results until the second half of 2027. Success in Sjögren's could have generated up to $1.4 billion in peak sales for that indication alone. A separate announcement of successful Phase 2 research into a celiac disease drug failed to offset investor concerns. Argenx acquired the medicine, FB102, through a $2.2 billion takeover of Forte Biosciences this year. TD Securities analyst Yaron Werber models $988 million in peak sales for the celiac drug. Despite the setback, Argenx maintains a market cap of around $50 billion. Vyvgart sales reached $1.5 billion in the second quarter alone.

Yahoo Finance
Oct 5th, 2026
10 analysts set Argenx price targets above $1,200 as biotech's revenue surges 60%

Argenx, a biopharmaceutical company with a market capitalisation near $60 billion, has caught the attention of Wall Street analysts. Ten analysts predict the biotech stock will reach at least $1,200 over the next 12 months, up from around $919 as of 2 October 2026. Wells Fargo and UBS set the highest price targets at $1,415 and $1,400 respectively, representing potential gains exceeding 50%. The average price target amongst 21 analysts stands at approximately $1,182, suggesting 29% upside. All but one analyst recommends buying the stock. Argenx's optimism stems from strong performance, delivering $1.5 billion in global product net sales last quarter, up 60% year over year. Its flagship drugs Vyvgart and Vyvgart Hytrulo drive growth, with additional approvals for autoimmune diseases potentially forthcoming.

ReachMD
Sep 30th, 2026
argenx to Present New VYVGART Data in MG and CIDP, Plus Pipeline Results, at AANEM 2026.

argenx to Present New VYVGART Data in MG and CIDP, Plus Pipeline Results, at AANEM 2026. 09/30/2026 Key Takeaways * argenx will present data on its portfolio and pipeline at the AANEM Annual Meeting and the MGFA Scientific Session, September 29 to October 2 in Orlando, Florida, including four oral presentations and dozens of posters. * New VYVGART (efgartigimod) results include deepening improvement in ocular myasthenia gravis (MG), sustained one-year efficacy in anti-AChR antibody-negative generalized MG (gMG), real-world data on earlier treatment, and long-term and switch data in chronic inflammatory demyelinating polyneuropathy (CIDP). * argenx will also present Phase 2 empasiprubart data in multifocal motor neuropathy (MMN) and Phase 1b adimanebart data in DOK7 congenital myasthenic syndrome (CMS). argenx, an Amsterdam-based immunology company, announced it will present clinical, long-term, and real-world data for VYVGART (intravenous efgartigimod alfa-fcab) and VYVGART Hytrulo (subcutaneous efgartigimod alfa and hyaluronidase-qvfc), along with results for two pipeline candidates. Chief Medical Officer Luc Truyen, M.D., Ph.D., said the data show how far the evidence for VYVGART reaches, across years of treatment and into patient populations historically left out of clinical trials. In MG, the company will present three sets of findings: * Ocular MG. In the Phase 3 ADAPT OCULUS study, patient-reported ocular scores on the Myasthenia Gravis Impairment Index (MGII) improved further after two VYVGART cycles beyond the placebo-controlled period. Scores went from -4.5 to -6.8 points in patients with anti-AChR antibodies and from -2.7 to -4.5 points in triple-seronegative patients. The company says the results build on evidence for VYVGART's potential as the first targeted treatment for ocular MG.

Yahoo Finance
Sep 26th, 2026
Argenx stock tipped for 23% gain on $1.5B revenue surge and Vyvgart expansion

Argenx stock has gained roughly 14% year-to-date, with Wall Street analysts projecting a potential 23% upside over the next 12 months. The biotech company has delivered 18 consecutive quarters of revenue growth. In Q2 2026, Argenx's global product net sales surged 60% year over year to $1.5 billion, with a 17% quarter-over-quarter increase. The Vyvgart franchise, treating chronic autoimmune disorders, drives growth following May 2026 FDA approval making it the first treatment for all serotypes of adults with generalised myasthenia gravis. Approximately 24,000 US patients receive treatment for chronic inflammatory demyelinating polyneuropathy, with half not well-managed on current therapy. Argenx reported positive Phase 3 results for Vyvgart in ocular myasthenia gravis earlier this year, with regulatory filing underway.